Australia backs infectious disease innovation as US funding faces more cuts

Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD $8.5 million available to support a new cohort of Australian innovators developing technologies for the prevention of infectious disease.

Established with $32.9 million in funding through the Medical Research Future Fund (MRFF) BioMedTech Incubator Grant Opportunity, the funding enables Biointelect to support the development and advancement of high-potential infectious disease innovations, helping promising technologies progress through critical development and commercialisation stages.

The initiative comes against a backdrop of growing global debate over the role and funding of infectious disease research. In the US, infectious disease specialists have raised concerns over a Trump administration plan to eliminate a clinical research unit and its associated funding at the National Institute of Allergy and Infectious Diseases (NIAID) for ten years.

The proposed changes have drawn strong criticism from US policymakers, including Senator Patty Murray, who warned of the broader implications.

“As if cancelling lifesaving medical research and clinical trials and firing cancer researchers en masse were not bad enough, the Trump administration is now trying to rob NIH [National Institutes of Health] of billions of dollars that Congress provided for medical research so that it can pad the Pentagon’s budget,” Senator Patty Murray said. “This outrageous agreement must be terminated immediately…We cannot allow this administration to shred patients’ hopes of new, lifesaving cures and treatments…”

The intersection of the Trump administration’s healthcare agenda and infectious disease management has further polarised public debate and consumer trust, while contributing to a changing environment for infectious disease therapies. The effects are also being felt in Australia, including through increased vaccine hesitancy.

Against this wider policy landscape, organisations such as Biointelect Venturer are seeking to strengthen the domestic pipeline of technologies aimed at preventing infectious disease and translating scientific innovation into practical health outcomes.

The successful companies from Biointelect Venturer’s first round were announced recently at the Australian Vaccine Value Chain Conference in Sydney. The inaugural cohort included ENA Respiratory, SAMMvax, Saccharide Therapeutics, Ebivanta Therapeutics, Proboxis Biotechnology and AdaptiVax.

Biointelect Venturer General Manager Danielle Shand said the second round represented another opportunity to identify and accelerate promising Australian technologies addressing infectious disease prevention.

“We are looking for Australian SMEs, research teams and innovators with novel and differentiated solutions, strong science, a clear development pathway and the potential to deliver meaningful public health impact. Biointelect Venturer combines substantial non-dilutive funding with tailored, hands-on support, strategic guidance and networks to help companies address critical development gaps, strengthen their commercialisation pathway and progress toward investment readiness,” she said.

Biointelect CEO Leah Goodman said Australia had the scientific capability and innovative thinking required to tackle some of the world’s most pressing infectious disease challenges.

“It is important that we continue to strengthen the pipeline of technologies and companies capable of translating innovation into real-world health impact, and programs like Biointelect Venturer play a significant and valuable role in supporting this journey,” Goodman said.

Round 2 will be the second and final cohort intake under the current MRFF-funded BioMedTech Incubator Grant Opportunity. A dedicated follow-on and top-up funding round will also be made available to companies from both the Round 1 and Round 2 cohorts, supporting the continued advancement of high-potential infectious disease innovations beyond their initial funding.

Expressions of Interest (EOIs) for Round 2 will open on Monday, 21 September 2026, at 9am AEST.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.